Sai Life Sciences Limited – Investor Presentation Summary

Key Operational Highlights

  • Total employees: 4,400+
  • Active customers: 300+ across US, UK, EU, Japan
  • 19/25 of the largest pharmaceutical companies are customers
  • 34 Active NCE commercial molecules
  • 14 Phase III/pre-registration molecules
  • 5 Molecules from discovery to market
  • 155 Programs in the pipeline across multiple therapy areas
  • 65% of Discovery programs are now integrated

Key drivers of operational performance: Growing traction with global pharmaceutical companies, increasing adoption of integrated outsourcing model, progression of development and commercial pipeline, ramp-up of new capacity.

Segment-wise Performance

  • CDMO Revenue Mix: 62%
  • CRO Revenue Mix: 38%
  • 65% of revenues from customers in FY23-26 who availed more than one Discovery services

Explanation of significant changes in segment performance: Performance was broad-based with both CRO and CDMO delivering healthy growth.

Financial Highlights

Quarterly (Q2 FY27):

  • Revenue: ₹659 crore
  • EBITDA: ₹187 crore
  • PAT: ₹98 crore
  • EBITDA Margin: 28%
  • PAT Margin: 14.9%

Half-Yearly (H1 FY27):

  • Revenue: ₹1,213 crore
  • EBITDA: ₹335 crore
  • PAT: ₹172 crore
  • EBITDA Margin: 28%
  • PAT Margin: 14.2%

YoY Comparison (Q2):

  • Revenue growth: 23% (from ₹537 crore in Q2 FY26)
  • EBITDA: ₹187 crore vs ₹156 crore in Q2 FY26
  • PAT: ₹98 crore vs ₹84 crore in Q2 FY26

Drivers of financial performance: Higher revenue growth, continued business momentum across key strategic priorities.

Key Risks: Not explicitly disclosed in the presentation.

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not specified in the presentation.

Regional Breakdown: Global presence with research laboratories in Greater Boston, US and Manchester, UK, and manufacturing facilities in India. Active customers across US, UK, EU, Japan.

Balance Sheet Snapshot

As of September 2026:

  • Property, plant, and equipment: ₹1,741 crore
  • Right of use of assets: ₹287 crore
  • Capital work in progress: ₹560 crore
  • Total non-current assets: ₹2,762 crore
  • Total current assets: ₹1,441 crore
  • Total assets: ₹4,202 crore
  • Total equity: ₹2,688 crore
  • Total non-current liabilities: ₹329 crore
  • Total current liabilities: ₹1,185 crore
  • Borrowings (current): ₹418 crore
  • Cash and bank balances: ₹59 crore

Financial Health Insights: Significant investment in capacity expansion with capital work in progress of ₹560 crore.

Capex & Cash Flow Health

  • Capital Expenditure: ₹621 crore incurred in H1 FY27 (Q2 at ₹358 crore)
  • On track for overall capex projection of ₹1,100 to ₹1,300 crore for FY27
  • Free Cash Flow: Not specified
  • Operating Cash Flow: Not specified
  • Net Debt Movement: Not specified

Investment Rationale: Focus on capacity and capability expansion to support customers over the long term.

Strategic & R&D Initiatives

Investments in Innovation:

  • Opened first building at Unit 8
  • Broke ground for new Process R&D Block at Unit 2 Hyderabad, doubling PRD capacity
  • Adding capabilities in early phase peptide development and clinical formulations
  • Building additional production capacity at Unit 4, Bidar
  • Acquired land for new greenfield site in Choutuppal
  • Expanding capabilities in ADCs, TPDs, Peptides, CGTs, Oligos

Expected impact on growth: Supporting long-term customer needs and expanding service offerings.

Strategic Rationale: Expanding into high-growth markets and new modalities, strengthening integrated CRDMO platform.

Industry Trends & Business Environment

Macro/Industry Trends: Growing traction with global pharmaceutical companies, increasing adoption of integrated outsourcing model.

Impact on Company: Customer engagements evolving from individual projects into larger, more strategic relationships spanning discovery, development and manufacturing.

Management Commentary & Growth Outlook

Strategic Outlook: "We see growing traction with global pharmaceutical companies, increasing adoption of our integrated outsourcing model, and continued progress in building the capacity and capabilities required to support customers over the long term." - Krishna Kanumuri, MD & CEO

FY Guidance: Expect a stronger second half, supported by progression of development and commercial pipeline and ramp-up of new capacity.

Market Share Targets: Not specified.

Risks and Opportunities: Not explicitly highlighted beyond forward-looking statement caveats.

ESG Updates

  • Unit 2 and Unit 4 received Zero Waste to Landfill Platinum certification, with over 95% of waste diverted from landfills
  • 100% renewable energy at Bidar site
  • Zero Liquid Discharge: water-neutral operations
  • Carbon roadmap approved by SBTi
  • Low-emission logistics via DHL
  • Platinum rating by EcoVadis
  • Certified Great Place To Work® for 2026–27

Digital Transformation

  • 85% digitization of R&D and Mfg processes
  • Digitization process expected to be complete by 2027
  • Interactive Business Intelligence dashboards using realtime data
  • AI/ML Manufacturing Process Prediction Model proof-of-concept outcome expected in 2026